Immunogenicity of Mycobacterium ulcerans Hsp65 and protective efficacy of a Mycobacterium leprae Hsp65-based DNA vaccine against Buruli ulcer

This publication has 17 references indexed in Scilit:

• Infection withMycobacterium ulceransInduces Persistent Inflammatory Responses in Mice
  Infection and Immunity, 2005
• Efficacy of the Combination Rifampin-Streptomycin in Preventing Growth of Mycobacterium ulcerans in Early Lesions of Buruli Ulcer in Humans
  Antimicrobial Agents and Chemotherapy, 2005
• Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin
  Cellular Microbiology, 2005
• Buruli Ulcer (M. ulcerans Infection): New Insights, New Hope for Disease Control
  PLOS Medicine, 2005
• Protective Efficacy of a DNA Vaccine Encoding Antigen 85A from Mycobacterium bovis BCG against Buruli Ulcer
  Infection and Immunity, 2001
• Therapy of tuberculosis in mice by DNA vaccination
  Nature, 1999
• Differential Protective Efficacy of DNA Vaccines Expressing Secreted Proteins ofMycobacterium tuberculosis
  Infection and Immunity, 1999
• Mycolactone: A Polyketide Toxin from Mycobacterium ulcerans Required for Virulence
  Science, 1999
• Vaccination against tuberculosis by DNA injection
  Nature Medicine, 1996
• The protective effect of BCG against Mycobacterium ulcerans disease: a controlled trial in an endemic area of Uganda
  Transactions of the Royal Society of Tropical Medicine and Hygiene, 1976